Literature DB >> 12843176

Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y.

Jaana Kallio1, Ullamari Pesonen, Ulriikka Jaakkola, Matti K Karvonen, Hans Helenius, Markku Koulu.   

Abstract

Neuropeptide Y (NPY) is an important neurotransmitter in the central and peripheral nervous systems. It has a regulatory role in cardiovascular and metabolic functions and control of hormone release. The leucine 7 to proline 7 (Leu7Pro) polymorphism in the signal peptide of prepro-NPY is associated with increased blood lipid levels, accelerated atherosclerosis, and diabetic retinopathy. This study elucidated the role of this polymorphism in diurnal cardiovascular, metabolic, and hormonal functions of healthy subjects during rest. The two study groups comprised individuals with different genotype, but they were matched for age and body mass index. Subjects with the Leu7Pro polymorphism had significantly lower plasma NPY and norepinephrine concentrations, lower insulin concentrations, higher glucose concentrations, and lower insulin-glucose ratio in plasma than the controls. Heart rate was significantly higher during daytime in the subjects with Leu7Pro polymorphism. Furthermore, these subjects had significantly lower prolactin concentrations in plasma. Systolic and diastolic blood pressure, serum free fatty acid and plasma leptin, ACTH, cortisol, LH, FSH, TSH, free thyroxin, and melatonin concentrations were similar during the 24-h period, compared with controls. These results show that genetically determined changes in NPY levels lead to widespread consequences in the control of sympathoadrenal, metabolic, and hormonal balance in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843176     DOI: 10.1210/jc.2002-021957

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Polymorphisms in the neuropeptide Y gene and the risk of obesity: findings from two prospective cohorts.

Authors:  Edwina H Yeung; Cuilin Zhang; Jinbo Chen; Katherine Bowers; Frank B Hu; Guolian Kang; Lu Qi
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

Review 2.  Neuropeptide Y T1128C polymorphism: an independent predictor of hypertensive and cardiovascular diseases?

Authors:  Jia L Zhuo
Journal:  J Hypertens       Date:  2004-07       Impact factor: 4.844

3.  Genetic variability in energy balance and pancreatic cancer risk in a population-based case-control study in Minnesota.

Authors:  Jianjun Zhang; Ishwori B Dhakal; Xuemei Zhang; Anna E Prizment; Kristin E Anderson
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

4.  Neuropeptide Y in the noradrenergic neurons induces the development of cardiometabolic diseases in a transgenic mouse model.

Authors:  Suvi T Ruohonen; Ullamari Pesonen; Eriika Savontaus
Journal:  Indian J Endocrinol Metab       Date:  2012-12

5.  The regulated secretory pathway and human disease: insights from gene variants and single nucleotide polymorphisms.

Authors:  Wei-Jye Lin; Stephen R Salton
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-06       Impact factor: 5.555

6.  Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges.

Authors:  Carmine Zoccali; Alberto Ortiz; Inga Arune Blumbyte; Sarina Rudolf; Annette G Beck-Sickinger; Jolanta Malyszko; Goce Spasovski; Sol Carriazo; Davide Viggiano; Justina Kurganaite; Vaiva Sarkeviciene; Daiva Rastenyte; Andreja Figurek; Merita Rroji; Christopher Mayer; Mustapha Arici; Gianvito Martino; Gioacchino Tedeschi; Annette Bruchfeld; Belinda Spoto; Ivan Rychlik; Andrzej Wiecek; Mark Okusa; Giuseppe Remuzzi; Francesca Mallamaci
Journal:  Nephrol Dial Transplant       Date:  2021-12-28       Impact factor: 5.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.